Third trial over Zantac cancer claims ends with hung jury
Adds response from plaintiff's attorney in paragraphs 2-3
By Brendan Pierson
Aug 7 (Reuters) -The third trial over claims that discontinued heartburn drug Zantac ended in a mistrial on Wednesday when jurors could not agree about whether pharmaceutical companyBoehringer Ingelheim was responsible for an Illinois man's cancer.
Martin Gross alleged in his lawsuit in state court in Chicago that he developed prostate cancer from a carcinogenic contaminant called NDMA found in the drug. His lawyer,Sean Grimsley, said he would take his case to trial again.
"We continue to believe in our case, in our cause and in our client," he said.
Boehringer Ingelheim said in a statement that it was "disappointed" that the jury had not reached a verdict and that "the totality of the scientific evidence" supports "only one conclusion: Zantac does not cause any type of cancer."
First approved by U.S. regulators in 1983, Zantac became the world's best-selling medicine in 1988 and one of the first to top $1 billion in annual sales. It was sold at different times by Boehringer Ingelheim, GSK GSK.L, Pfizer PFE.N and Sanofi SASY.PA, all of which have faced thousands of lawsuits.
Two such cases previously went to trial, both ending in verdicts for the defense - one for Boehringer Ingelheim and GSK in May, and the other for GSK on Monday.
Sanofi has agreed to settle about 4,000 cases against it, while Pfizer has reportedly agreed to settle more than 10,000. The companies have also settled some individual cases before trial.
The majority of the lawsuits are in Delaware state court, where a judge in June allowed more than 70,000 cases to go forward after rejecting the defendants' bid to keep key plaintiffs' expert witnesses out of court on the grounds that their scientific methods were not reliable. The companies are appealing that ruling.
The litigation began after the U.S. Food and Drug Administration in 2020 asked manufacturers to pull the drug off the market over concerns that ranitidine, the active ingredient in Zantac and generic versions of the drug, could degrade into NDMA over time or when exposed to heat.
The drugmakers have said the cases are meritless. They won a significant victory in 2022, when a Florida federal judge ruled against about 50,000 cases, finding that the alleged cancer link was not supported by sound science. Some of those cases are being appealed.
Reporting By Brendan Pierson in New York; Editing by Aurora Ellis and Diane Craft
Mga Kaugnay na Asset
Pinakabagong Balita
Disclaimer: Ang mga kabilang sa XM Group ay nagbibigay lang ng serbisyo sa pagpapatupad at pag-access sa aming Online Trading Facility, kung saan pinapahintulutan nito ang pagtingin at/o paggamit sa nilalaman na makikita sa website o sa pamamagitan nito, at walang layuning palitan o palawigin ito, at hindi din ito papalitan o papalawigin. Ang naturang pag-access at paggamit ay palaging alinsunod sa: (i) Mga Tuntunin at Kundisyon; (ii) Mga Babala sa Risk; at (iii) Kabuuang Disclaimer. Kaya naman ang naturang nilalaman ay ituturing na pangkalahatang impormasyon lamang. Mangyaring isaalang-alang na ang mga nilalaman ng aming Online Trading Facility ay hindi paglikom, o alok, para magsagawa ng anumang transaksyon sa mga pinansyal na market. Ang pag-trade sa alinmang pinansyal na market ay nagtataglay ng mataas na lebel ng risk sa iyong kapital.
Lahat ng materyales na nakalathala sa aming Online Trading Facility ay nakalaan para sa layuning edukasyonal/pang-impormasyon lamang at hindi naglalaman – at hindi dapat ituring bilang naglalaman – ng payo at rekomendasyon na pangpinansyal, tungkol sa buwis sa pag-i-invest, o pang-trade, o tala ng aming presyo sa pag-trade, o alok para sa, o paglikom ng, transaksyon sa alinmang pinansyal na instrument o hindi ginustong pinansyal na promosyon.
Sa anumang nilalaman na galing sa ikatlong partido, pati na ang mga nilalaman na inihanda ng XM, ang mga naturang opinyon, balita, pananaliksik, pag-analisa, presyo, ibang impormasyon o link sa ibang mga site na makikita sa website na ito ay ibibigay tulad ng nandoon, bilang pangkalahatang komentaryo sa market at hindi ito nagtataglay ng payo sa pag-i-invest. Kung ang alinmang nilalaman nito ay itinuring bilang pananaliksik sa pag-i-invest, kailangan mong isaalang-alang at tanggapin na hindi ito inilaan at inihanda alinsunod sa mga legal na pangangailangan na idinisenyo para maisulong ang pagsasarili ng pananaliksik sa pag-i-invest, at dahil dito ituturing ito na komunikasyon sa marketing sa ilalim ng mga kaugnay na batas at regulasyon. Mangyaring siguruhin na nabasa at naintindihan mo ang aming Notipikasyon sa Hindi Independyenteng Pananaliksik sa Pag-i-invest at Babala sa Risk na may kinalaman sa impormasyong nakalagay sa itaas, na maa-access dito.